Tumor-derived exosomes induce PD1+ macrophage population in human gastric cancer that promotes disease progression

Furong Wang1,2,3, Bin Li4, Yucai Wei5,6, Yang Zhao2, Li Wang5, Peng Zhang1,2, Jinwei Yang2, Wenting He2, Hao Chen2,6, Zuoyi Jiao2,6 and Yumin Li2,3,6

Abstract

Macrophages constitute a major component of tumor-infiltrating immune cells. M2 macrophages have been reported to promote tumor progression through promoting tumor angiogenesis and metastasis and regulating T-cell function. Here, we identified a protumorigenic subset of macrophages that constitutively expressed programmed cell death 1 (PD1) and accumulated in advanced-stage gastric cancer (GC). These PD1+ tumor-associated macrophages (TAMs) exhibited an M2-like surface profile, with a significant increase in the expression of CD206, IL-10, and CCL1, and a clear decrease in the expression of MHC class II, CD64, and IL-12 and the ability to phagocytose ovalbumin. Moreover, PD1+ TAMs can suppress CD8+ T-cell function and this immunosuppressive activity can effectively be enhanced upon triggering PD1 signal. GC-derived exosomes effectively educated monocytes to differentiate into PD1+ TAMs with M2 phenotypic and functional characteristics. Together, our results are the first to show that GC-derived exosomes can effectively induce PD1+ TAM generation, and these cells can produce a large number of IL-10, impair CD8+ T-cell function, and thereby create conditions that promote GC progression. Thus, methods in which immunotherapy is combined with targeting PD1+ TAMs and tumor-derived exosomes should be used to restore immune function in GC patients.

Introduction

Gastric cancer (GC), which is the fourth most common malignant tumor, is the third leading cause of cancer-related death in the world1. Helicobacter pylori (HP) infection is the main risk factor for the progression of chronic gastritis2 which is mainly composed of extracellular matrix, activated cancer-associated fibroblasts, and immune cells, such as myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), regulatory T cells (Treg), and regulatory B cells (Breg), which accelerates GC progression. However, the key roles and underlying mechanisms of these immune cells are still understood.

Macrophages (Mφs) are a major component of tumor-infiltrating immune cells3,4, and associate with poor prognosis in tumor5. Recent studies have confirmed that TAMs can accelerate tumor angiogenesis6, metastasis7, and influence the T-cell activation and differentiation via the cytokine secretion8,9. However, TAMs have been confirmed to possess phenotypic plasticity which can be divided into the polarized states of M1 and M210. The PD1 is one of the best-studied and most clinically successful immune-checkpoint drug targets11, but its function is well confirmed to regulate T-cell function.

Correspondence: Zuoyi Jiao (jiaozy@lzu.edu.cn) or Yumin Li (lym@lzu.edu.cn)
1Department of Pathology, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College, Lanzhou, China
2Gansu Provincial Key Laboratory of Digestive System Tumors, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College, Lanzhou, China
Full list of author information is available at the end of the article
These authors contributed equally: Furong Wang, Bin Li, Yucai Wei.
also express PD1 and these PD1\(^+\) TAMs exhibit M2 phenotypic characteristics which favor tumor progression by inhibiting antitumor immunity.\(^{15}\) Thus, we wondered whether GC-derived macrophages might also express PD1, and if so, how PD1\(^+\) TAMs are induced.

Exosomes are the small intraluminal vesicles with the diameter range from 30 to 200 nm. Exosomes have been reported to mediate local and systemic cell-to-cell communication through the delivery of information, such as microRNAs, mRNAs, cDNA, and proteins.\(^{16-19}\) Tumor-derived exosomes have been reported to accelerate primary tumor growth,\(^{20,21}\) and accelerate tumor growth,\(^{22}\) tumor invasion, and metastases\(^{23-25}\) through the transfer of DNA, RNA, and proteins. Because of these observations, we investigate whether tumor-derived exosomes are involved in the PD1\(^+\) TAM production in GC progression.

### Materials and methods

**Human mononuclear cells separation**

GC tissue was cut into small pieces with a size of about 0.1 cm and digested in RPMI 1640 containing 0.01% DNase I (Roche, Basel, Switzerland), 0.08% type IV collagenase (Sigma-Aldrich, St. Louis, Missouri, USA), and 15% fetal bovine serum (FBS) (HyClone, Ogden, Utah, USA). The digestion cells were filtered via a 150-μm filter, and then the mononuclear cells (MCs) were separated by density-gradient centrifugation. The MCs were collected and resuspended in PBS containing 1% heat-inactivated FBS for flow cytometry analysis. To analyze the function of PD1\(^+\) macrophages, PD1\(^+\) macrophages were purified from MCs using flow cytometry.

**Flow cytometry**

The antibodies (Abs) were BV421, PE-\(\gamma\), APC-\(\gamma\), or FITC-conjugated mouse anti-human Abs: CD45, CD8\(^{\text{a}}\), CD8\(^{\text{b}}\), CD4\(^{\text{b}}\), CD14, and CD68 (Dako), and rabbit anti-human PD1 (R&D Systems) and CD8 Ab at 4°C for 30 min. Then, the cells were washed twice, fixed with 1% paraformaldehyde solution. Flow cytometry analysis was performed using FACScan and Flow Jo software.

**Enzyme-linked immunosorbent assay**

Human IL-10, IL-12p70, and CCL1 concentrations of the culture media from macrophages were analyzed using Enzyme-linked immunosorbent assay (ELISA) kits following the manufacturers’ instructions (R&D Systems for CCL1; eBioScience for IL-12p70 and IL-10).

**Real-time polymerase chain reaction**

Total RNA was extracted and determined using an SYBR Green real-time PCR kit. PCR products were determined by electrophoresis on 2% agarose gel and photographed after ethidium bromide staining.

**Immunofluorescence**

Paraffin-fixed GC tissues were cut into 5-μm sections and carried out using a two-step protocol. In total, 5-μm sections were stained with the Abs: mouse anti-human CD68 (Dako), and rabbit anti-human PD1 (R&D Systems) at 4°C for 16 h, followed by fluorescently labeled secondary Abs at 37°C for 30 min.

**T-cell proliferation and cytokine production assays**

To analyze the functions of PD1\(^+\) macrophages, 5,000,000 CD8\(^+\) T cells were cultured in 10 ml of PBS supplemented with 25 μM carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen, Carlsbad, CA, USA) at 37°C for 5 min, washed twice, and seeded at 100,000 cells in a 96-well round plate with 200 μl of RPMI 1640 medium supplemented with 10% FBS. PD1\(^+\) macrophages were obtained from tumor tissue using flow cytometry and added to CD8\(^+\) T-cell culture system at ratios of 1:1. Then, the CD8\(^+\) T cells were stimulated with 1 μl of anti-CD3 and 2 μl of anti-CD28 beads for 3 days. Finally, the

### Table 1 Clinicopathological characteristics of gastric-cancer patients (n = 26)

| Variables                              | No. and (%) |
|----------------------------------------|-------------|
| No. of patients                        | 20          |
| Age (median; range), years             | 59; 21–72   |
| Gender (male/female)                   | 17/9 (65.0/35.0) |
| Tumor size, cm (≤4/4)                  | 10/16 (40.0/60.0) |
| Tumor location (higher/middle/lower/other) | 10/4/8/4 (40.0/15.0/30.0/15.0) |
| TNM stage (IA/IB/IIA/IIIB/IV)          | 1/4/9/6/3/3 (5.0/15.0/35.0/25.0/100/100) |
| Gastric cancer subtype (common types/special type) | 20/6 (77/23) |
Fig. 1 (See legend on next page.)
proliferation and perforin and IFN-γ expression in CD8+ T cells were determined using flow cytometry. In some experiments, PD1+ macrophages were pretreated with PD1 functional Ab (goat human-specific AF1086, R&D Systems) and total goat IgGs (R&D Systems) for 24 h, washed twice, and added to CD8+ T-cell culture system at ratios of 1:1.

**Endocytosis assay of macrophages**

To evaluate the phagocytic ability, PD1+ macrophages were incubated for 30 min at 37 °C, with FITC-conjugated ovalbumin (OVA; 100 mg/mL; Sigma-Aldrich) in RPMI 1640 containing 10% FBS. Then, the cells were washed twice with PBS containing 0.5% BSA and 0.1% NaN3 and resuspended in PBS containing 0.1% NaN3 and 0.5% BSA for immediate evaluation by flow cytometry.

**GC exosome isolation and monocyte culture**

Human gastric-cancer cell lines such as SGC7901 and BGC823, were purchased from the American Type Culture Collection (Rockville, MD, USA). Culture media from SGC7901 and BGC823 which were cultured with exosome-depleted serum were collected on day 3, and centrifuged at 1500 rpm for 10 min. Supernatants were centrifuged at 2500 rpm for 20 min, and then passed through 0.22-µm filters. Exosomes were obtained by mixing with ExoQuick-TC (System Biosciences) following the manufacturers’ instructions. Exosomes were resuspended in PBS, and total protein of exosomes was quantified by BCA assay. Isolated exosomes (50 µg) were added into the monocytes culture system for 3 days.

**Statistical analysis**

The differences between groups were analyzed by Bonferroni post test. Correlations between groups were determined by Pearson’s correlation analysis as appropriate. A value of $p < 0.05$ was considered significant.

**Results**

PD1+ macrophages are enriched in gastric-cancer tissues and associated with poor patient survival

To evaluate the PD1 expression of TAMs in an immunocompetent syngeneic setting, we first analyzed its expression pattern in GC tissues. We used flow cytometry to study the PD1 expression of macrophages in 26 GC specimens (paired blood, non-tumor tissue, and intra-tumor tissue; Table 1), and found that intratumoral macrophages expressed a significantly higher level of PD1 than those expressed on non-tumor tissue macrophages, whereas peripheral macrophages expressed little PD1 (Fig. 1a–c). Furthermore, we used immunofluorescence staining to study the expression of PD1 on macrophages in 15 GC specimens (paired non-tumor tissue, and intra-tumor tissue; Table 2). The results also showed that PD1+ macrophages were accumulated at GC tissue (Fig. 1d, e).

Next, we assessed the clinical relevance of intratumorous PD1+ macrophages in GC patients (Tables 1 and 2), and found that the proportions of PD1+ macrophages determined by flow cytometry were significantly associated with disease progression in 26 GC patients (Fig. 1f, Table 1), and that the number of PD1+ macrophages determined by immunofluorescence staining was also significantly associated with disease progression in 15 GC patients (Fig. 1g, Table 2). Importantly, using 24 months as the cutoff, we found that patients with higher proportions of PD1+ macrophages in tumor showed early...
Fig. 2 (See legend on next page.)
recurrence of GC (Fig. 1h). Thus, these results show that PD1⁺ macrophages selectively accumulated at the tumor that associate with disease progression and early recurrence in GC patients.

**Phenotypic and functional characteristics of PD1⁺ macrophages in GC patients**

We compared the phenotypic features of GC-infiltrating PD1⁺ macrophages and PD1⁻ macrophages. FACS analysis of typical M1 and M2 markers confirmed that PD1⁺ and PD1⁻ macrophages from GC tissues expressed more of the M2-associated surface molecules such as CD206, and less CD64 and MHC class II (Fig. 2a–d).

To further determine the functional characteristics of PD1⁺ macrophages, we analyzed their cytokine expression using ELISA and q-PCR. Correspondingly, the PD1⁺ macrophages derived from GC tissues expressed higher levels of M2 markers IL-10 and CCL1, but not M1 marker IL-12p70, than PD1⁻ macrophages (Fig. 2e, f). We then evaluated the phagocytosis levels of PD1⁺ macrophages by analyzing the proportion of OVA⁺ macrophages. FACS analysis of PD1⁻ vs. PD1⁺ macrophages showed that PD1⁻ macrophages phagocytosed significantly lower OVA in vitro than PD1⁺ macrophages (Fig. 2g, h).

**PD1⁺ macrophages exhibit immunosuppressive activity and triggering PD1 enhances this suppressive function**

To investigate whether PD1⁺ macrophages could inhibit the function of CD8⁺ T cells, human autologous peripheral blood CD8⁺ T cells were activated by anti-CD3/CD28 mAb beads, and PD1⁺ macrophages and PD1⁻ macrophages were added at 1:1 ratio. The result showed that PD1⁺ macrophages significantly reduced the proportion of CD8⁺ T cells (Fig. 3a, b). Moreover, IFN-γ and perforin expression in CD8⁺ T cells decreased distinctly in the PD1⁺ macrophage group compared with the PD1⁻ macrophage group (Fig. 3c–f).

We also analyzed whether the PD1 signal contributes to the suppressive effects of PD1⁺ macrophages. A PD1⁻ specific agonist significantly enhanced the ability of the PD1⁺ macrophages to inhibit the proliferation (Fig. 3g), and IFN-γ and perforin expressions of CD8⁺ T cells (Fig. 3h). These findings reveal a novel mechanism involving PD1⁺ macrophage suppressive function mediated by the PD1 signal.

**PD1⁺ macrophages are negatively correlated with CD8⁺ T cells in GC tissue**

To analyze the potential function of PD1⁺ macrophages in immune cells, we investigate the correlation between the percent of PD1⁺ macrophages and lymphocytes in GC tissues. The results showed that the percent of PD1⁺ macrophages was negatively correlated with CD8⁺ T cells (Fig. 4b), but was not correlated with CD4⁺ T cells (Fig. 4a). These data showed that the protumorigenic activity of PD1⁺ macrophages might be mediated via influencing CD8⁺ effector T cells.

**Tumor-derived exosomes can promote PD1⁺ macrophages expansion from monocytes in vitro and in vivo**

Interestingly, recent studies demonstrated exosomes, in particular, tumor-cell-derived exosomes, a plethora of immunomodulatory activities on dampening T-cell responses. Thus, we hypothesized that gastric-cancer cells-derived exosomes can induce PD1⁺ macrophage production.

To evaluate the role of GC-derived exosomes in promoting PD1⁺ macrophage expansion, we exposed monocytes to secreted exosomes isolated from SGC7901 gastric cancer cell line. The isolation of exosomes was confirmed by Nano-sight, western blotting, and flow cytometry for the exosomal marker CD63 (Fig. 5a). Treatment with exosomes resulted in an increase in PD1 expression of monocytes (Fig. 5c, d). Moreover, exosomes coculture also led to the marked upregulation of the M2-associated scavenger receptor CD206 (Fig. 5b).

To further confirm the role of exosomes in the production of PD1⁺ macrophages, we determined their cytokine expression patterns, phagocytosis levels, and immunosuppressive activity. Exposure of monocytes to exosomes from SGC7901 and BGC823 led to an increase in IL-10 (Fig. 5e) and CCL1 expression (Fig. 5f), but a decrease in IL-12p70 expression (Fig. 5g). Moreover, FACS analysis showed that exosome-treated monocytes phagocytosed significantly lower OVA than monocytes cultured alone (Fig. 5h). The downregulation of IFN-γ, and perforin expression (Fig. 5i, j) and an increased ability
Fig. 3 (See legend on next page.)
that GC effector macrophages express strong immunosuppressive activity. a, b CFSE-labeled CD8+ T cells were activated by anti-CD3/CD28 beads, and PD1+ T, and PD1+ macrophages derived from GC tissue were added at 1:1 ratio. After 3 days, these cells were stained with anti-CD8 Ab, and the expression of IL10 in CD8+ T cells was analyzed. Representative flow cytometry plots are shown in (a). Results represent the mean of three independent experiments. c, d Isolated CD8+ T cells were activated by anti-CD3/CD28 beads, and PD1+, and PD1+ macrophages derived from GC tissue were added at 1:1 ratio. After 3 days, these cells were labeled with anti-CD8 and IFN-γAb, and the expression of IFN-γ in CD8+ T cells in NO TAM, PD1+ TAM, and PD1– TAM was analyzed. Representative flow cytometry plots are shown in (c, d). Results represent the mean of three independent experiments.

Fig. 3 PD1+ macrophages exhibit strong immunosuppressive activity. a, b CFSE-labeled CD8+ T cells were activated by anti-CD3/CD28 beads, and PD1+, and PD1+ macrophages derived from GC tissue were cocultured with PD1+ macrophages (Fig. 5n, o). Thus, these results show that GC efficiently induces PD1+ macrophages from circulating monocytes by the secretion of exosomes.

Discussion

Here, we reported an unrecognized immunosuppressive PD1+ macrophage subset and depict the phenotype, biological function, mechanisms of induction, and clinical relevance of those cells in GC patients.

The PD1 signal is one of the best-studied and most clinically successful immune-checkpoint drug targets, and its primary function is widely understood to regulate T-cell function. However, the expression and role of PD1 on other immune cells is poorly understood. Previous studies have reported that macrophages expressed significantly higher levels of PD1 during the context of pathogen infection12–14, which resulted in macrophage dysfunction. Here, we provide evidence that TAMs from GC patients also share markedly increased PD1 levels, which promotes GC progression by impairing the antitumor functions of CD8+ T cells. These data are consistent with the observation that TAMs from colorectal cancer increase PD1 expression and that PD1 expression inhibits TAM’s phagocytosis and tumor immunity15.

TAMs have been found to polarize toward an inflammatory M1 or pro-tumor M2 state, depending on their environmental stimuli26, and distinct TAM populations differed at the surface profile and function27. Our results show that PD1+ TAMs express an M2-like surface...
Fig. 5 (See legend on next page.)
Collectively, our data provide a new insight into possible manipulation of PD1+ TAM-mediated immunosuppression in gastric cancer. Exosomes derived from gastric-cancer cells effectively induce the production of PD1+ TAMs. After interacting directly with PD1+ cells, the PD1+ TAMs produce a large number of IL-10, induce the dysfunction of CD8+ T cell, and thereby create conditions that are favorable to GC progression. Accordingly, methods in which immunotherapy is combined with targeting PD1+ TAMs and tumor-derived exosomes should be used to restore immune function in GC patients.

Acknowledgements
This work was supported by National Natural Science Foundation of China (Grant IDs: 31270532 and 2015DFAS1650).

Author details
1Department of Pathology, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College, Lanzhou, China. 2Gansu Provincial Key Laboratory of Digestive System Tumors, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College, Lanzhou, China. 3School of Life Sciences, Lanzhou University, Lanzhou 730000, China. 4Department of Thoracic Surgery, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College, Lanzhou, China. 5School of Basic Medical Science, Lanzhou University, Lanzhou 730000, China. 6Department of General Surgery, Lanzhou University Second Hospital, Lanzhou University Second Clinical Medical College, Lanzhou, China.

Conflict of interest
The authors declare that they have no conflict of interest.

Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 22 September 2017 Revised: 16 December 2017 Accepted: 1 April 2018
Published online: 25 May 2018

References
1. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015).
2. Plummer, M., Franceschi, S., Vignat, J., Forman, D. & de Martel, C. Global burden of gastric cancer attributable to Helicobacter pylori. Int. J. Cancer 136, 487–490 (2015).

molecule, such as a significant increase in the CD206, IL-10, and CCL1 expression, and a clear decrease in the MHC class II, CD64, and IL-12 expression and the ability to phagocytose OVA protein, whereas PD1+ TAMs show a trend toward the expression of an M1-like surface molecule. Functionally, PD1+ TAMs possess stronger immunosuppressive activity of CD8+ T-cell function compared with PD1+ TAMs, and this suppressive function can be effectively enhanced upon PD1 triggering. These results suggest that PD1 signal immunotherapies may also function through a direct effect on PD1+ TAMs, with substantial implications for the treatment of GC patients with these agents. We try to understand the underlying mechanism contributing to the accumulation and activation of PD1+ TAMs. With the emergence of exosomes as central players in tumor progression and metastatic niche formation and their expanding list of reported immune-regulatory activities, we hypothesized that exosomes derived from tumor could play a key role in regulating macrophage activation during GC progression. Interestingly, treatment of monocytes with exosomes derived from gastric-cancer cells led to an increase in the PD1 expression on monocytes. A significant increase in the CD206, IL-10, and CCL1 expression, and a clear decrease in the MHC class II, CD64, and IL-12 expression were observed in exosome-treated monocytes. Moreover, functional analysis shows that an increased capacity to suppress autologous CD8+ T-cell proliferation and IFN-γ expression was observed in exosome-treated monocytes. Moreover, the exosome release inhibitor spiroepoxide led to a distinct reduction in the proportion of PD1+ macrophages following exposure to exosomes. We used a tumor-bearing mouse model to analyze the induction of PD1+ macrophages by tumor exosomes, and found that the tumor could induce PD1+ macrophage generation and that the exosome release inhibitor spiroepoxide could impair these effects. These results show that gastric-cancer cells dramatically educate monocytes into PD1+ macrophages through the secretion of exosomes in vitro and in vivo.
1. Qian, B. Z. & Pollard, J. W. Macrophage diversity enhances tumor progression and metastasis. *Cell* **141**, 39–51 (2010).
2. Toh, B., Toh, B., Abasto, J. P. & Abasto, J. P. Myeloid cells: prime drivers of tumor progression. *Oncoimmunology* **1**, 1360–1367 (2012).
3. Pollard, J. W. Tumour-educated macrophages promote tumour progression and metastasis. *Nat. Rev. Cancer* **4**, 71–78 (2004).
4. Lewis, C. E., Harney, A. S. & Pollard, J. W. The multifaceted role of perivascular macrophages in tumors. *Cancer Cell* **30**, 18–25 (2016).
5. Chen, W., Wang, J., Jia, L., Liu, J. & Tian, Y. Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. *Cell Death Dis.* **7**, e2115 (2016).
6. Bally, A. P. et al. NF-kappaB regulates PD-1 expression in macrophages. *Leukemia* **20**, 2703–27033 (2016).
7. Lewis, C. E., Harney, A. S. & Pollard, J. W. The multifaceted role of perivascular macrophages in tumors. *Cancer Cell* **30**, 18–25 (2016).
8. Bally, A. P. et al. Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. *Front. Physiol.* **5**, 75 (2014).
9. Wang, B. et al. Association of intra-tumoral infiltrating macrophages and regulatory T cells is an independent prognostic factor in gastric cancer after radical resection. *Ann. Surg. Oncol.* **18**, 2585–2593 (2011).
10. Quatromoni, J. G. & Euslanov, E. Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. *Am. J. Transl. Res.* **4**, 376–389 (2012).
11. Bardhan, K., Aragnostou, T. & Boussios, V. A. The PD1-PD-L1/2 pathway from discovery to clinical implementation. *Front. Immunol.* **7**, 550 (2016).
12. Huang, X. et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. *Proc. Natl Acad. Sci. USA* **106**, 6303–6308 (2009).
13. Chen, W., Wang, J., Liu, J. & Tian, Y. Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. *Cell Death Dis.* **7**, e2115 (2016).
14. Bally, A. P. et al. NF-kappaB regulates PD-1 expression in macrophages. *J. Immunol.* **194**, 4545–4554 (2015).
15. Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. *Nature* **545**, 495–499 (2017).
16. Peinado, H., Lavotshkin, S. & Lyden, D. The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. *Semin. Cancer Biol.* **21**, 139–146 (2011).
17. Valadi, H. et al. Exosome-mediated transfer of miRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat. Cell Biol.* **9**, 654–659 (2007).
18. Ratajczak, J. et al. Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of miRNA and protein delivery. *Leukemia* **20**, 847–856 (2006).
19. Wang, W. et al. Characterization of the release and biological significance of cell-free DNA from breast cancer cell lines. *Oncotarget* **8**, 43180–43191 (2017).
20. Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat. Cell Biol.* **10**, 1470–1476 (2008).
21. Dickman, C. T. et al. Selective extracellular vesicle exclusion of miR-142-3p by oral cancer cells promotes both internal and extracellular malignant phenotypes. *Oncotarget* **8**, 15252–15266 (2017).
22. Melo, S. A. et al. Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer Cell* **26**, 707–721 (2014).
23. Sui, S., et al. Imaging exosome transfer from breast cancer cells to stroma at metastatic sites in orthotopic nude-mouse models. *Adv. Drug Deliv. Rev.* **65**, 383–390 (2013).
24. Hoshino, A. et al. Tumour exosome integrins determine organotrophic metastasis. *Nature* **527**, 329–335 (2015).
25. Monzo, M. et al. Exosomal microRNAs isolated from plasma of mesenteric veins linked to liver metastases in resected patients with colon cancer. *Oncotarget* **8**, 30859–30869 (2017).
26. Sca, A., Schioppa, T., Mantovani, A. & Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. *Eur. J. Cancer* **42**, 717–727 (2006).
27. Movahedi, K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. *Cancer Res.* **70**, 5728–5739 (2010).
28. Chen, Z. et al. Cytoskeleton-centric protein transportation by exosomes transforms tumor-favorable macrophages. *Oncotarget* **7**, 67387–67402 (2016).
29. Ying, X. et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. *Oncotarget* **7**, 43076–43087 (2016).
30. Yamada, N. et al. Colorectal cancer cell-derived extracellular vesicles induce phenotypic alteration of T cells into tumor-growth supporting cells with transforming growth factor-beta-mediated suppression. *Oncotarget* **7**, 25393–25403 (2016).
31. Ding, G. et al. Pancreatic cancer-derived exosomes transfer miRNAs to dendritic cells and inhibit RFXAP expression via miR-212-3p. *Oncotarget* **6**, 29877–29888 (2015).
32. Cobb, D. A., KIM, O. K., Golden-Mason, L., Rosen, H. R., & Hahn, Y. S. Hepatocyte-derived exosomes promote T follicular regulatory cell expansion during HCV infection. *Hepatology* **67**, 71–85 (2018).
33. Maybrick, B. T., Pfannenstiel, J. W., Diaz-Montero, M. & Gastman, B. R. Tumor-derived exosomes induce CD8+ T cell suppressors. *J. Immunother. Cancer* **5**, 65 (2017).